Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs BioNano Genomics Inc (BNGO) Price & Performance

Agilent Technologies IncTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Agilent Technologies Inc vs BioNano Genomics Inc — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.22B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Agilent Technologies Inc is far larger — about 3090.8× BioNano Genomics Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

ABNGO
Market Cap
$42.22B$13.66M
Sector
HealthHealth
52-Week High
$157.20$4.92
52-Week Low
$110.24$1.06
Enterprise Value
$43.77B$16.26M
Dividend Yield
0.68%

Returns comparison

Trailing returns across standard periods

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO